



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_291_26

You asked:

Under the Freedom of Information Act 2000, I am requesting information regarding the prescribing of dupilumab (Dupixent - BNF presentation codes in section 03.04.02) commissioned through the NHS Wales Joint Commissioning Committee (JCC, formerly the Welsh Health Specialised Services Committee / WHSSC), and dispensed across the seven Welsh Local Health Boards.

All requested data should be provided as monthly aggregate counts. Please apply standard NHS statistical disclosure control rules and suppress any cell with a count below 5. Where indication-attribution is not routinely held in a single source, please provide what is available from your standard reporting and indicate which fields are not held.

1) New patient initiations by indication, monthly.

For each calendar month from January 2022 to the date of this request, please provide the number of patients newly approved for / newly initiated on dupilumab through JCC (or formerly WHSSC) commissioning, broken down by the indication recorded at point of approval. Categories of interest: -

Severe asthma (eosinophilic / type-2 high)

Chronic obstructive pulmonary disease (COPD)

Atopic dermatitis

Chronic rhinosinusitis with nasal polyposis (CRSwNP)

Eosinophilic oesophagitis (EoE)

Prurigo nodularis

Other / not recorded

2) Prevalent patient counts by indication, monthly.

For the same period, please provide the total number of patients receiving ongoing dupilumab treatment funded through JCC / WHSSC commissioning at each month-end, broken down by the same indication categories as Q1.

3) Total dispensed volume and spend, monthly.

For the same period, please provide the total monthly dispensed quantity of dupilumab (in number of pre-filled pen / pre-filled syringe units, summed across all strengths) and the total monthly spend (£, ex VAT) across all NHS Wales Local Health Boards. If indication-attribution is not available at dispensing-grain, the un-broken totals are acceptable. If JCC does not hold dispensing-grain data centrally, please indicate where this is held (e.g. NWSSP) and the unbroken totals at the level you do hold.

Our response:

We can confirm that the NWJCC does not hold the information required as it does not commission the listed conditions:

- Severe asthma (eosinophilic / type-2 high)
- Conic obstructive pulmonary disease (COPD)
- Atopic dermatitis
- Chronic rhinosinusitis with nasal polyposis (CRSwNP)
- Eosinophilic oesophagitis (EoE)
- Prurigo nodularis

Responsibility for providing the above listed services lies with the individual Health Boards.